231 related articles for article (PubMed ID: 26739998)
21. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: a randomised, multicentre, open-label, phase 2 trial.
Hironaka S; Sugimoto N; Yamaguchi K; Moriwaki T; Komatsu Y; Nishina T; Tsuji A; Nakajima TE; Gotoh M; Machida N; Bando H; Esaki T; Emi Y; Sekikawa T; Matsumoto S; Takeuchi M; Boku N; Baba H; Hyodo I
Lancet Oncol; 2016 Jan; 17(1):99-108. PubMed ID: 26640036
[TBL] [Abstract][Full Text] [Related]
22. A phase II study of biweekly S-1 and paclitaxel (SPA) as first-line chemotherapy in patients with metastatic or advanced gastric cancer.
Jiang H; Qian J; Zhao P; Zhang X; Zheng Y; Mao C; Zheng Y; Chen L; Wang Y; Mou H; Fang W; Teng L; Xu N
Cancer Chemother Pharmacol; 2015 Jul; 76(1):197-203. PubMed ID: 26013324
[TBL] [Abstract][Full Text] [Related]
23. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
[TBL] [Abstract][Full Text] [Related]
24. A phase I trial of S-1 with oxaliplatin in patients with relapsed and metastatic colorectal cancer.
Kim HS; Park MJ; Uhm JE; Lee Y; Lee HY; Kang EM; Lee J; Park SH; Park JO; Lim HY; Kang WK; Park YS
Int J Colorectal Dis; 2009 Nov; 24(11):1311-6. PubMed ID: 19609538
[TBL] [Abstract][Full Text] [Related]
25. A phase II study of biweekly oxaliplatin plus S-1 combination chemotherapy as a first-line treatment for patients with metastatic or advanced gastric cancer in China.
Xiao C; Qian J; Zheng Y; Song F; Wang Q; Jiang H; Mao C; Xu N
Medicine (Baltimore); 2019 May; 98(20):e15696. PubMed ID: 31096513
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of 3-weekly combination chemotherapy using epirubicin, oxaliplatin, and S-1 (EOS) in patients with previously untreated advanced gastric cancer.
Sym SJ; Hong J; Jung M; Park J; Cho EK; Lee WK; Chung M; Kim HS; Lee JH; Shin DB
Cancer Chemother Pharmacol; 2012 Aug; 70(2):277-84. PubMed ID: 22752217
[TBL] [Abstract][Full Text] [Related]
27. 'A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combined with oxaliplatin (TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer'.
Bennouna J; Perrier H; Paillot B; Priou F; Jacob JH; Hebbar M; Bordenave S; Seitz JF; Cvitkovic F; Dorval E; Malek K; Tonelli D; Douillard JY
Br J Cancer; 2006 Jan; 94(1):69-73. PubMed ID: 16404362
[TBL] [Abstract][Full Text] [Related]
28. Biweekly S-1 plus oxaliplatin (SOX) reintroduction in previously treated metastatic colorectal cancer patients (ORION 2 study): a phase II study to evaluate the efficacy and safety.
Tanioka H; Honda M; Tanaka C; Morita Y; Ishibashi K; Kato T; Matsuda C; Kataoka M; Satake H; Munemoto Y; Kobayashi K; Takahashi M; Nakata K; Sakamoto J; Oba K; Mishima H
Int J Clin Oncol; 2019 Jul; 24(7):836-841. PubMed ID: 30778794
[TBL] [Abstract][Full Text] [Related]
29. Retrospective analysis of S-1 monotherapy in patients with metastatic colorectal cancer after failure to fluoropyrimidine and irinotecan or to fluoropyrimidine, irinotecan and oxaliplatin.
Yasui H; Yoshino T; Boku N; Onozawa Y; Hironaka S; Fukutomi A; Yamazaki K; Taku K; Kojima T; Machida N
Jpn J Clin Oncol; 2009 May; 39(5):315-20. PubMed ID: 19403734
[TBL] [Abstract][Full Text] [Related]
30. Concurrent irinotecan, oxaliplatin and UFT in first-line treatment of metastatic colorectal cancer: a phase I study.
Sheikh HY; Valle JW; Palmer K; Sjursen A; Craven O; Wilson G; Swindell R; Saunders MP
Br J Cancer; 2007 Jan; 96(1):38-43. PubMed ID: 17213824
[TBL] [Abstract][Full Text] [Related]
31. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
32. The SOFT trial: a Phase III study of the dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine S-1 and oxaliplatin (SOX) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer.
Nakamura M; Yamada Y; Muro K; Takahashi K; Baba H; Sasaki Y; Komatsu Y; Satoh T; Mishima H; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Future Oncol; 2015; 11(10):1471-8. PubMed ID: 25963425
[TBL] [Abstract][Full Text] [Related]
33. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
[TBL] [Abstract][Full Text] [Related]
34. Clinical study of tegafur-gimeracil-oteracil potassium capsule (s-1) and oxaliplatin combination chemotherapy in advanced colorectal cancer.
Liu H; Wang Y; Li G; Song W; Wang R
J Cancer Res Ther; 2015; 11(2):331-5. PubMed ID: 26148595
[TBL] [Abstract][Full Text] [Related]
35. Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
Winther SB; Österlund P; Berglund Å; Glimelius B; Qvortrup C; Sorbye H; Pfeiffer P;
BMC Cancer; 2017 Aug; 17(1):548. PubMed ID: 28814275
[TBL] [Abstract][Full Text] [Related]
36. Irinotecan, oxaliplatin, and 5-fluorouracil/leucovorin combination chemotherapy in advanced colorectal carcinoma: a phase II study.
Calvo E; Cortés J; Rodríguez J; Fernández-Hidalgo O; Rebollo J; Martín-Algarra S; García-Foncillas J; Martínez-Monge R; de Irala J; Brugarolas A
Clin Colorectal Cancer; 2002 Aug; 2(2):104-10. PubMed ID: 12453325
[TBL] [Abstract][Full Text] [Related]
37. [Assessment of quality of life by questionnaires between S-1/CPT-11 and mFOLFOX6 in patients with advanced colorectal cancer].
Tokunaga Y; Sasaki H; Matsueda S
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1127-31. PubMed ID: 21772096
[TBL] [Abstract][Full Text] [Related]
38. A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer.
Takahara N; Isayama H; Nakai Y; Sasaki T; Hamada T; Uchino R; Mizuno S; Miyabayashi K; Kogure H; Yamamoto N; Sasahira N; Hirano K; Ijichi H; Tateishi K; Tada M; Koike K
Cancer Chemother Pharmacol; 2013 Nov; 72(5):985-90. PubMed ID: 23995699
[TBL] [Abstract][Full Text] [Related]
39. UFT/leucovorin and oxaliplatin alternated with UFT/leucovorin and irinotecan in metastatic colorectal cancer.
Petrioli R; Sabatino M; Fiaschi AI; Marsili S; Pozzessere D; Messinese S; Correale P; Civitelli S; Tanzini G; Tani F; De Martino A; Marzocca G; Lorenzi M; Giorgi G; Francini G
Br J Cancer; 2004 Jan; 90(2):306-9. PubMed ID: 14735168
[TBL] [Abstract][Full Text] [Related]
40. Mitomycin-C in combination with fluoropyrimidines in the treatment of metastatic colorectal cancer after oxaliplatin and irinotecan failure.
Alkis N; Demirci U; Benekli M; Yilmaz U; Isikdogan A; Sevinc A; Ozdemir NY; Koca D; Yetisyigit T; Kaplan MA; Uncu D; Unek T; Gumus M
J BUON; 2011; 16(1):80-3. PubMed ID: 21674854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
